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Autoimmune lymphoproliferative syndrome in
pregnancy: A case of favorable mother–fetal outcome in
a well-controlled disease
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Abstract
The autoimmune lymphoproliferative syndrome (ALPS) is a disorder of abnormal lymphocyte survival caused
by the dysregulation of the Fas apoptotic pathway. The Fas gene is expressed at the maternal–fetal interface and
is involved in the regulation of immune response and implantation. Altered Fas expression may result in
altered apoptosis and, ultimately, affect both the immune response and implantation; it is in fact associated
with recurrent pregnancy loss, preterm premature rupture of the membrane and pre-eclampsia. Currently,
there are over 500 cases of ALPS reported worldwide from various racial and ethnic backgrounds. Up to date,
the published work contains no specific reports on pregnancy outcome in women affected by ALPS. We
present a case of full-term uneventful pregnancy in a patient affected by ALPS. A specific clinical follow-up in
a pregnant woman with primary immunologic disease is suggested.
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Introduction
Autoimmune LYMPHOPROLIFERATIVE SYN-
DROME (ALPS) is, generally, an early onset (24 months
of age) primary immunologic disease, consisting of a
disorder of abnormal lymphocyte survival caused by
the dysregulation of the Fas–apoptotic pathway.1 Five
hundred cases of ALPS are currently reported world-
wide from various racial and ethnic backgrounds.2 The
syndrome is characterized by autoimmunity, non-
malignant lymphoproliferation, secondary malignan-
cies (an increased risk of B-cell lymphoma), as well as
by the presence of a rare T-cell population expressing
T-cell receptor (TCR)-αβ+ CD3+ CD4− CD8−, known as
double-negative (DN) cells, in the peripheral blood.2,3
Lymphoproliferation may present as lymphadenopa-
thy, splenomegaly and hepatomegaly. Over 70% of
patients develop an autoimmune disease, commonly
multilineage cytopenias (e.g. hemolytic anemia, throm-
bocytopenia, autoimmune neutropenia).4 Other auto-
immune manifestations such as nephritis, hepatitis,
urticaria, arthritis, colitis and pulmonary fibrosis are
less frequent. Fas and Fas ligand (FasL) interact
through the Fas-activating death domain (FADD), trig-
gering the caspase cascade, culminating in DNA deg-
radation, proteolysis and apoptosis.5 During
pregnancy, the uterus and the placenta are immuno-
logically privileged sites in which the immune activity
is effectively diminished; immune cells apoptosis has
been identified as a mechanism for maintaining
immune privilege.6 Fas and the FasL system is
expressed at the maternal–fetal interface and it is
involved in pregnancy physiology in the first trimes-
ter.7 On the other hand, its dysregulation is related to
pathological processes such as recurrent pregnancy
loss, premature rupture of the membrane and pre-
eclampsia.8–10 Moreover, the presence of an autoim-
mune disease is also associated with clinical conditions
that negatively affect pregnancy (e.g. thrombocytope-
nia, infections and, in particular, complications due to
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surgical cuts). We report a case of full-term uneventful
pregnancy in a patient affected by ALPS and suggest a
specific follow-up in a pregnant woman with primary
immunologic disease.
Case Report
A 23-year-old Caucasian woman, with a body mass
index (BMI) of more than 30, zero para and known to
have ALPS, was referred to the high-risk obstetric unit
of our department at 13 weeks of gestation. Her
medical history began at 22 months of age, when she
presented splenomegaly, neutropenia, thrombocytope-
nia and autoimmune hemolytic anemia. She was trans-
fused and treated with corticosteroid therapy. Nine
years later, due to an episode of severe hemolysis resis-
tant to medical treatment, she underwent splenectomy
and was treated with 1 000 000 IU of benzylpenicillin
every 15 days in order to avoid post-splenectomy
sepsis. Until the age of 23 years, she was administrated
cycles of prednisone at different doses and 200 mg of
cyclosporin daily. During this period, she presented
different exacerbation of the disease with thrombocy-
topenia (platelets, <5000), arthritis and eczema. In 2012,
she stopped the treatment with cyclosporin because
of high blood pressure and remained free from
symptoms.
The patient presented at our department at 13 weeks
of pregnancy on current treatment with 12.5 mg of
prednisone daily, 1 000 000 IU of benzylpenicillin
every 15 days and 5 mg of folate daily; because of the
lack of teratogenicity of prednisone and benzylpenicil-
lin and their positive effect on the maternal disease,
assumption of the regular drugs was recommended till
delivery. Pregnancy, although unplanned, started
spontaneously during a remission phase after a
12-month disease. All laboratory blood tests were
within normal range. Immunologic markers, lupus
anticoagulant, antiphospholipid and anti-Ro antibod-
ies were negative; antinuclear antibodies were posi-
tive. She underwent an abdominal ultrasound scan
including lymph node evaluation and a cardiovascular
examination that were unremarkable. During preg-
nancy, the following control schedule was proposed in
an outpatient regimen: every 2 weeks maternal clinical
parameters (blood pressure, heart frequency, weight
increase) and blood tests (red blood cells, white blood
cells and platelets count; assessment of acute-phase
reactants and evaluation of liver and kidney function)
were measured to monitor the mother’s autoimmune
hemolytic anemia and thrombocytopenia; every 3
weeks a fetal ultrasound scan was performed (in order
to assess fetal growth, spleen size and middle cerebral
artery flow) until the third trimester in order to exclude
an in utero onset of fetal disease. At 16 weeks of gesta-
tion, ultrasound scan did not show fetal abnormalities,
except for a hyperechoic bowel. The patient underwent
planned genetic counseling, during which she was
informed about the autosomal dominant transmission
of ALPS. Cystic fibrosis screening of both parents was
performed and tested negative. Amniocentesis was
carried out without any complications and the fetal
karyotype was normal (46, XY). At 22 weeks of gesta-
tion, the morphologic ultrasound evaluation did not
show fetal anomalies and fetal spleen size appeared
normal. The ultrasounds performed until the third tri-
mester did not show signs of hepatosplenomegaly and
fetal anemia. From the 30th week of gestation, fetal
cardiotocography was performed once a week. At 36
weeks, the patient was hospitalized for a threatening
preterm delivery. During admission, routine analysis
and fetal scans were in the normal range. An emer-
gency cesarean section was performed at 38 weeks due
to the diagnosis of a genital wart and a not reassuring
non-stress test. She delivered a healthy boy weighing
3706 g; his blood count was completely normal. After
delivery, the clinical condition of the patient and the
blood laboratory tests were within normal range.
The patient received antibiotic therapy (cefazolin 2 g,
metronidazole 500 mg, t.i.d. for 5 days) and
thromboprophylaxis with enoxaparine 6000 once a day
for 6 weeks. After 6 days, the abdominal wound
showed signs of local infection and dehiscence. A
pelvic and abdominal ultrasound was performed to
exclude a pelvic abscess and the presence of free intra-
peritoneal fluid; the uterus was regularly positioned.
After 4 weeks, a surgical curettage of the wound and a
re-suture were performed. A few days later, the patient
was in good clinical condition and discharged back
home. The follow-up at 6 months from delivery was
negative for the mother and the baby.
Discussion
Autoimmune lymphoproliferative syndrome was first
identified as a clinical entity by Canale and Smith in
1967.11 In 1992, a genetic mutation in the ‘death recep-
tor’ Fas was discovered in a mouse model exhibiting
lymphoproliferation. Shortly after, mutations in the
same molecule were shown to underlie the human
disease, and was known as ALPS thereafter. The main
molecular causes of ALPS are mutations in the death
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receptor Fas (80%), its ligand (2%) and caspase-10
(2%).1 In childhood, the mutations result in the accu-
mulation of proliferating lymphocytes triggering
chronic lymphadenopathy, splenomegaly, multilineage
cytopenias secondary to sequestration and autoim-
mune destruction, and to an increased risk of B-cell
lymphoma. The latest National Institutes of Health
(NIH) revision of ALPS diagnostic criteria from the
2009 international workshop is divided into two
required and six accessory criteria. Required criteria
include the presence of lymphadenopathy and/or sple-
nomegaly, and elevated TCR-αβ+ DNT cells. Accessory
criteria are subdivided into primary ones, which
include an abnormal lymphocyte apoptosis assay and
the presence of pathogenic mutations in the Fas
pathway genes; and secondary criteria, which include
the presence of elevated circulating biomarkers, char-
acteristic histopathology, the combined presence of
autoimmune cytopenias, polyclonal
hypergammaglobulinemia and family history compat-
ible with ALPS.2 Over 70% of patients with ALPS have
identifiable mutations in Fas pathway genes.4 In order
to downregulate the normal immune response, acti-
vated B and T lymphocytes increase Fas expression and
activated T lymphocytes increase the expression of
FasL. Both Fas and FasL are localized in the chorionic
villi and the decidual layers. The Fas gene is known to
be expressed at the maternal–fetal interface and to play
an important role in the immune response regulation.
The T-helper (Th)1/Th2 activity ratio is critical for
normal pregnancy. The apoptosis of cytotoxic T lym-
phocytes is essential for the maternal immune toler-
ance during pregnancy. It has been reported that the
activation of T lymphocytes by foreign antigens
induces the expression of Fas, which upon binding to
FasL, initiates a cascade of the apoptotic pathway that
eliminates lymphocytes and suppresses the immune
response.12 The role of these mechanisms has been
recently discovered in physiological pregnancy devel-
opment and maintenance. Cell death through apopto-
sis is essential for maintaining the normal invasion of
the embryo, and for the embryo immune tolerance.7
Implantation involves proliferation, differentiation and
apoptosis in order to accommodate the growing con-
ceptus. Rapid morphologic changes that influence the
placenta development take place in the maternal
deciduas.13 The decidua undergoes a characteristic tem-
poral and spatial pattern of regression through the
process of apoptosis, which is also essential for suc-
cessful fetal–placental development.7 Some studies on
mice deficient in Fas–FasL show that this defect has no
adverse effect on pregnancy outcome.14 Conversely,
disturbances in programmed cell death in the placenta
seem to be associated with abnormal pregnancy
outcome: the loss of Fas expression and defective apop-
tosis are associated with recurrent pregnancy loss,
preterm premature rupture of the membrane and pre-
eclampsia.8–10 Furthermore, lymphoproliferation with
anomalies of the Fas–FasL system characterized by
autoimmunity that resembles systemic LES (i.e. throm-
bocytopenia, autoimmune hemolytic anemia, nephri-
tis), together with an increase in the risk of infections,
may negatively affect pregnancy. Up to date, the pub-
lished work contains no specific reports of pregnancy
outcome in women affected by ALPS. Only a case of in
utero early onset of fetal ALPS in a family with a novel
Fas mutation has been reported.15 We will describe a
pregnant patient diagnosed with ALPS at 24 months
according to the NIH criteria: splenomegaly, neutrope-
nia, thrombocytopenia and autoimmune hemolytic
anemia. Pregnancy had a physiological course, despite
the genetic defect of the maternal FADD system; the
only complication was the infection of the surgical
wound probably due to multiple risk factors linked to
ALPS, corticosteroid therapy and a high BMI. ALPS
complications were not detected during pregnancy, or
in the first 6 months of follow-up after delivery. In our
opinion, the uneventful pregnancy may be related,
above all, to the long remission phase of the disease at
the onset of pregnancy and to the appropriate medical
treatment during pregnancy; we suggest monitoring
both the mother for autoimmune hemolytic anemia
and thrombocytopenia during pregnancy with an
appropriate surveillance plan and the fetus (fetal
spleen size and middle cerebral artery flow), in order
to exclude an early onset of in utero disease. The timing
and modality of delivery are an individual choice
which derives from a balance between primarily
obstetric indications, the maternal risk of infections
and the possible consequences on the fetus. Further
knowledge on pregnancy in women affected by ALPS
may improve the insight into mechanisms involved in
fetal–placental pathologies.
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